911 related articles for article (PubMed ID: 19573471)
21. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
[TBL] [Abstract][Full Text] [Related]
22. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Fox KA; Granger CB; Jolly S; Rupprecht HJ; Widimsky P; Yusuf S;
Am Heart J; 2008 Dec; 156(6):1080-1088.e1. PubMed ID: 19033002
[TBL] [Abstract][Full Text] [Related]
23. Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis.
Saito T; Fujisaki T; Aikawa T; Kampaktsis PN; Malik A; Briasoulis A; Takagi H; Wiley J; Slipczuk L; Kuno T
Int J Cardiol; 2023 Oct; 389():131157. PubMed ID: 37433404
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
[TBL] [Abstract][Full Text] [Related]
25. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
[TBL] [Abstract][Full Text] [Related]
26. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
28. Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a real-life setting: the final report (J-PLACE Final).
Ako J; Morino Y; Okuizumi K; Usami M; Nakamura M
Cardiovasc Interv Ther; 2016 Apr; 31(2):101-13. PubMed ID: 26449481
[TBL] [Abstract][Full Text] [Related]
29. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
[TBL] [Abstract][Full Text] [Related]
30. Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTE-ACS).
Morino Y; Ako J; Kobayashi M; Nakamura M
Cardiovasc Interv Ther; 2014 Apr; 29(2):123-33. PubMed ID: 24307536
[TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
32. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Ebrahimi R; Dyke C; Mehran R; Manoukian SV; Feit F; Cox DA; Gersh BJ; Ohman EM; White HD; Moses JW; Ware JH; Lincoff AM; Stone GW
J Am Coll Cardiol; 2009 May; 53(21):1965-72. PubMed ID: 19460609
[TBL] [Abstract][Full Text] [Related]
33. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease.
Cheng JW
J Manag Care Pharm; 2007 May; 13(4):326-36. PubMed ID: 17506599
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of prasugrel in a US managed care population.
Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES
J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985
[TBL] [Abstract][Full Text] [Related]
36. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
[TBL] [Abstract][Full Text] [Related]
37. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
38. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
[TBL] [Abstract][Full Text] [Related]
39. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Ho PM; Peterson ED; Wang L; Magid DJ; Fihn SD; Larsen GC; Jesse RA; Rumsfeld JS
JAMA; 2008 Feb; 299(5):532-9. PubMed ID: 18252883
[TBL] [Abstract][Full Text] [Related]
40. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
